The therapeutic landscape for hormone receptor–positive, HER2-negative breast cancer is currently undergoing a paradigm shift, characterized by the expansion of oral selective estrogen receptor degraders (SERDs) and targeted therapies into…
Earlier Use of CDK4/6 Inhibitors, Oral SERDs Reflects Shift Toward Proactive Management of HR+ Breast Cancer
